Clinical Utilization of MRD in Multiple Myeloma: an in-depth view

The aim of this programme is to improve your knowledge surrounding the measurement, clinical application and interpretation of measurable residual disease (MRD) in multiple myeloma.

Through completing this activity, participants will be able to:

  1. Understand the potential uses of MRD in the newly diagnosed setting, and the controversies surrounding these
  2. Gain knowledge of the different methods of measuring MRD, and the pros and cons of each
  3. Explore what MRD status in the relapsed setting could mean for patients and what further research is needed in this area

All content has been developed with the US experience in mind, but the learning programme will be informative for healthcare professionals from any country.

The MRD Focus on VJHemOnc is supported by Abbvie, Janssen Pharmaceuticals (a Johnson & Johnson Company) and MMRF. These supporters have no influence over the production of the content.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter